Last reviewed · How we verify

NCT05743816: neoAMRO

Neonatal Antimicrobial Resistance and Outcome

Status unknown Last updated 1 March 2023
What this trial tests

trial in Neonatal Infection in 800 participants. Status unknown.

Timeline
30 July 2019
Primary endpoint
30 September 2023
29 February 2024

Quick facts

Lead sponsorSt George's, University of London
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment800
Start date30 July 2019
Primary completion30 September 2023
Estimated completion29 February 2024
Sites1 location across United Kingdom

Conditions studied

Sponsor

St George's, University of London

Who can join

Adults 28 Days to 12 Months, any sex, with Neonatal Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicentre observational study involving NNUs across the UK. Study personnel (Neonatologists and research Nurses) from these NNUs will identify eligible babies in whom a positive culture has been obtained. This study will help identify the infections leading to death in babies on UK neonatal units, define the clinical characteristics of babies dying from infections, and describe the management of babies dying from infections with a specific focus in their antimicrobial treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Neonatal Infection

Currently open trials in the same condition.

Other St George's, University of London trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05743816.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing